TVTX · earnings call history
Travere Therapeutics Q2 FY26 — Exceptional FILSPARI Growth and Pipeline Advancement
Read the briefTravere Therapeutics Q1 FY26 — FILSPARI FSGS Approval and Record IgAN Demand Drive Growth
Read the briefBrowse all US companies on the earnings-call register.